- Home
- Products
- Customized ADCs
- EGFR
- Anti-EGFR-EDC/NHS-Dox ADC
Anti-EGFR-EDC/NHS-Dox ADC (CAT#: ADC-W-503)
This ADC product is comprised of an anti-EGFR monoclonal antibody conjugated via a EDC/NHS linker to Dox. The Dox is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Dox binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- EGFR
- Alternative Names
- epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian
- Target Entrez Gene ID
- 1956
- Target UniProt ID
- P00533
- Overview
- The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene.
- Overview
- Chimeric Anti-EGFR lgG1 Antibody
- Species Reactivity
- Human
- Name
- EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide)
- Description
- Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
- Name
- Doxorubicin
- Description
- Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-503. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2592 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-505 | Anti-EGFR (cetuximab)-EDC/NHS-methotrexate ADC | EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide) | methotrexate (MTX) |
| ADC-W-2587 | Anti-EGFR (Zalutumumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-504 | Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
| CAT# | Product Name | Linker | Payload |
| ADC-W-505 | Anti-EGFR (cetuximab)-EDC/NHS-methotrexate ADC | EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide) | methotrexate (MTX) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-340 | Anti-TNFRSF8-DIBO-doxorubicin ADC-12 | DIBO (dibenzylcyclooctynol) | doxorubicin |
| ADC-W-479 | Anti-CD74-SMCC-Dox ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
| ADC-W-571 | Anti-ERBB2 (Trastuzumab)-DOX ADC | thiomaleamicacids-p-aminobenzyloxycarbonyl | doxorubicin |
| ADC-W-578 | Anti-CD74-MCC-Dox ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | doxorubicin |
| ADC-W-339 | Anti-CD22-DIBO-doxorubicin ADC | DIBO (dibenzylcyclooctynol) | doxorubicin |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-MUC16 (Sofituzumab)-SMCC-DM1 ADC (CAT#: ADC-W-2565)
- Anti-CD40 (Teneliximab)-SPDB-DM4 ADC (CAT#: ADC-W-903)
- Anti-VEGFA (Ranibizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1938)
- Anti-CEACAM1 (Arcitumomab)-MC-MMAF ADC (CAT#: ADC-W-964)
- Anti-AOC3 (Vapaliximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-672)
- Anti-CD22 (Moxetumomab pasudotox)-MC-MMAF ADC (CAT#: ADC-W-802)
- Anti-CD4 (Priliximab)-MC-MMAF ADC (CAT#: ADC-W-862)
- Anti-EGFR-Mc-MMAF ADC-5 (CAT#: ADC-W-515)
- Anti-CD22-MCC-DM1 ADC-11 (CAT#: ADC-W-484)
- Anti-FcrL5-Mc-VC-PABC-MMAE ADC-4 (CAT#: ADC-W-501)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.